A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast C.pdf (303.24 kB)
A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer; does trastuzumab interfere With the outcome?
journal contribution
posted on 2023-06-10, 04:21 authored by Maryam Joudi, Maryam Moradi Binabaj, Pejman Porouhan, Babak PeyroShabany, Mohsen Tabasi, Danial Fazilat-Panah, Mahtab Khajeh, Arezoo Mehrabian, Mansoureh Dehghani, James S Welsh, Batol Keykhosravi, Azam Akbari Yazdi, Mona Ariamanesh, Ahmad Ghasemi, Gordon FernsGordon Ferns, Seyed Alireza JavadiniaAim To determine the efficacy and safety of inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer. Methods In this multi- institutional cohort study, a total of 160 breast cancer patients (mean age of 50.01 ± 11.5 years old) were assessed for the SARS-CoV-2 Anti-Spike IgG and SARS-CoV2 Anti RBD IgG by ELISA after two doses of 0.5 mL inactivated, COVID-19 vaccine (BBIBP-CorV). All patients were followed up for three months for clinical COVID-19 infection based on either PCR results or imaging findings. Common Terminology Criteria for Adverse Events were used to assess the side effects. Results The presence of SARS-CoV-2 anti-spike IgG, SARS-CoV2 anti-RBD IgG, or either of these antibodies was 85.7%, 87.4%, and 93.3%. The prevalence of COVID-19 infection after vaccination was 0.7%, 0% and 0% for the first, second and third months of the follow-up period. The most common local and systemic side-effects were injection site pain and fever which were presented in 22.3% and 24.3% of patients, respectively. Discussion The inactivated SARS-CoV-2 vaccine (BBIBP-CorV) is a tolerable and effective method to prevent COVID-19.
History
Publication status
- Published
File Version
- Published version
Journal
Frontiers in EndocrinologyISSN
1664-2392Publisher
Frontiers Media SAExternal DOI
Volume
13Page range
1-7Event location
SwitzerlandDepartment affiliated with
- Division of Medical Education Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2022-07-28First Open Access (FOA) Date
2022-07-28First Compliant Deposit (FCD) Date
2022-07-28Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC